SCHEMBL22354542

SCHEMBL22354542

O=C(O)CCC(=O)NC1CCNCC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.67
GNAI3 P08754 1/20 0.58
GNAO1 P09471 1/20 0.58
GNAI1 P63096 1/20 0.58
EPHX1 P07099 5/20 0.55
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.47
CHRM5 P08912 1/20 0.44
CHRM3 P20309 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
HPGD P15428 1/20 0.42
EPHX2 P34913 2/20 0.41
HDAC3 O15379 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC10 Q969S8 2/20 0.41
HDAC11 Q96DB2 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
NCOR2 Q9Y618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10015691 0.86 ALDH1A1 (0.80) ALDH1A1EPHX1SMN1; SMN2HPGDEPHX2
SCHEMBL3520525 0.82 GNAI3 (0.60) ALDH1A1GNAI3GNAO1GNAI1EPHX1
SCHEMBL18536761 0.82 ALDH1A1 (0.88) ALDH1A1EPHX1POLBSMN1; SMN2HPGD
SCHEMBL11981666 0.81 GNAI3 (0.73) ALDH1A1GNAI3GNAO1GNAI1EPHX1
SCHEMBL28172495 0.81 GNAI3 (0.58) ALDH1A1GNAI3GNAO1GNAI1EPHX1
SCHEMBL23419601 0.80 ALDH1A1 (1.00) ALDH1A1EPHX1SMN1; SMN2HPGDEPHX2
SCHEMBL20650992 0.80 ALDH1A1 (1.00) ALDH1A1EPHX1SMN1; SMN2HPGDEPHX2
SCHEMBL22061771 0.80 ALDH1A1 (1.00) ALDH1A1EPHX1SMN1; SMN2HPGDEPHX2
SCHEMBL12292825 0.80 ALDH1A1 (1.00) ALDH1A1EPHX1SMN1; SMN2HPGDEPHX2
SCHEMBL10078357 0.80 ALDH1A1 (1.00) ALDH1A1EPHX1SMN1; SMN2HPGDEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137819-A1 FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY INC (US) 2026-05-21 US disclosed
EP-4598928-A1 FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF Radionetics Oncology, Inc. (US) 2025-08-13 EP disclosed
WO-2024077006-A1 FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-04-11 WO disclosed
EP-3035938-B1 TARGETED THERAPEUTICS MADRIGAL PHARMACEUTICALS INC (US) 2020-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137819-A1 FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF FSHR, GNRHR, LHCGR ALDH1A1 3439/4885GNAI3 3289/4885GNAO1 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.